Effect of esketamine combined with cervical plexus block on depression and anxiety after thyroid cancer surgery

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200066199

Enrollment

Unknown

Registered

2022-11-28

Start date

2022-12-01

Completion date

Unknown

Last updated

2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative depression and anxiety

Interventions

control group:Induction + maintenance + postoperative analgesia : sufentanil

experimental group:Induction + maintenance + postoperative analgesia : esketamine

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Clear diagnosis and general anesthesia operation indications; 2. ASA grade I-II; 3. BMI 18 ~ 28kg / m^2; 4. Aged 18-65 years old; 5. No severe cardiopulmonary disease; 6. Normal mental and cognitive function; 7. Patients voluntarily signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Emergency surgery; 2. Patients with severe respiratory, digestive, neurological, blood, liver and kidney function, malignant tumors and other diseases; 3. Patients with a history of sedative or analgesic drugs 3 months before operation ; 4. Operation time > 2h or anesthesia time > 2.5h; 5. iIcomplete bilateral cervical plexus block; 6. Patients who may have drug allergy or contraindications during anesthesia.

Design outcomes

Primary

Measure	Time frame
depression scores;anxiety scores;cortisol;brain-derived neurotrophic factor(BDNF);	—

Countries

China

Contacts

Public ContactHaiyu Xie

First Affiliated Hospital of Gannan Medical College

huamomojiao@163.com+86 187 0959 9092

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026